Ovid Therapeutics (OVID) Accumulated Expenses (2016 - 2026)

Ovid Therapeutics has reported Accumulated Expenses for 11 years, with the latest figure at $5.4 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 9.74% year-over-year to $5.4 million; the trailing twelve-month figure through Mar 2026 stood at $5.4 million (down 9.74% YoY), and the FY2025 full-year result was $4.9 million, down 18.27% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $5.4 million, up from $4.9 million in the prior quarter.
• The five-year high for Accumulated Expenses was $8.1 million in Q2 2024, with the low at $2.2 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $5.1 million across 5 years, with a median of $5.4 million in 2026.
• Annual changes were most pronounced in 2022 — Accumulated Expenses plunged 83.51% — and 2023, when it jumped 87.74%.
• Ovid Therapeutics' Accumulated Expenses stood at $4.5 million in 2022, then jumped by 44.83% to $6.5 million in 2023, then retreated by 8.12% to $6.0 million in 2024, then slipped by 18.27% to $4.9 million in 2025, then increased by 10.49% to $5.4 million in 2026.
• The last three Accumulated Expenses figures came in at $5.4 million (Q1 2026), $4.9 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.